Longer than you might think
GLP-1 medications feel like a recent phenomenon, driven by the cultural wave around semaglutide and tirzepatide over the past few years. But the drug class itself is two decades old, and its scientific roots go back further still. This guide covers the full history, every approved medication in the U.S. with its manufacturer and approval year, a side-by-side comparison, and the medications still in the pipeline.
Where it started
The GLP-1 hormone itself was identified in the 1980s as part of research into gut hormones that regulate insulin. The breakthrough that made drug development possible came from an unexpected source: exendin-4, a peptide found in the saliva of the Gila monster, a venomous lizard. Exendin-4 activates the same receptor as human GLP-1 but resists the rapid breakdown that limits natural GLP-1's usefulness as a drug — this discovery became the basis for the first approved GLP-1 medication.
The full approval timeline
| Year (approx.) | Medication | Generic name | Manufacturer | Notes |
|---|---|---|---|---|
| 2005 | Byetta | Exenatide | Amylin Pharmaceuticals (later Eli Lilly / AstraZeneca) | First GLP-1 receptor agonist approved; twice-daily injection; derived from exendin-4 |
| 2010 | Victoza | Liraglutide | Novo Nordisk | Once-daily injection for type 2 diabetes |
| 2012 | Bydureon | Exenatide (extended-release) | Amylin / AstraZeneca | Once-weekly version of exenatide |
| 2014 | Tanzeum | Albiglutide | GSK | Once-weekly; discontinued by manufacturer in 2017-2018 for commercial reasons, not safety |
| 2014 | Trulicity | Dulaglutide | Eli Lilly | Once-weekly injection for type 2 diabetes |
| 2014 | Saxenda | Liraglutide (weight-management dose) | Novo Nordisk | First GLP-1 approved specifically for chronic weight management |
| 2016 | Adlyxin | Lixisenatide | Sanofi | Once-daily; approved earlier in Europe as Lyxumia (2013) |
| 2017 | Ozempic | Semaglutide | Novo Nordisk | Once-weekly injection for type 2 diabetes |
| 2019 | Rybelsus | Semaglutide (oral) | Novo Nordisk | First oral GLP-1 medication |
| 2021 | Wegovy | Semaglutide (weight-management dose) | Novo Nordisk | Approved specifically for chronic weight management |
| 2022 | Mounjaro | Tirzepatide | Eli Lilly | First dual GIP/GLP-1 agonist; approved for type 2 diabetes |
| 2023 | Zepbound | Tirzepatide (weight-management dose) | Eli Lilly | Dual agonist approved for chronic weight management |
| 2025-2026 | Foundayo | Orforglipron | Eli Lilly | First oral, non-peptide GLP-1 medication approved for weight management |
Approval years reflect U.S. FDA approval and are approximate for older medications; always confirm current status directly with the FDA or manufacturer, since this list reflects the picture as of this writing and the field continues to move quickly.
How to think about the comparison
A few patterns are worth understanding rather than just memorizing the table:
- Dosing frequency has generally decreased over time — from twice-daily (exenatide) to once-daily (liraglutide) to once-weekly (dulaglutide, semaglutide, tirzepatide) injections, and now to a once-daily oral option (orforglipron/Foundayo) that doesn't require injection at all.
- The same active ingredient is often sold under two brand names — one for diabetes, one for weight management, typically at a higher maintenance dose for the weight-management version. Ozempic/Wegovy (semaglutide) and Mounjaro/Zepbound (tirzepatide) are the clearest examples — see our guide on understanding insurance coverage for why this distinction matters for coverage.
- Later drugs generally show larger average weight loss in trials — single-pathway GLP-1 drugs (semaglutide) generally outperformed earlier ones (liraglutide, exenatide), and the dual GIP/GLP-1 agonist tirzepatide has generally outperformed single-pathway GLP-1 drugs, reflecting the field's progression toward multi-hormone targeting (see our glossary entries on dual agonist and GLP-1 vs. dual agonist).
- Not every approved drug survived commercially. Albiglutide (Tanzeum) is a reminder that FDA approval doesn't guarantee a drug stays on the market — it was discontinued for business reasons despite being approved and effective.
What's still in the pipeline (not yet approved)
Several next-generation candidates are in various stages of clinical trials as of this writing, though none are FDA-approved yet — treat timelines as uncertain and confirm current status before relying on them:
- Retatrutide (Eli Lilly) — a "triple agonist" activating GLP-1, GIP, and glucagon receptors together; see our glossary entry on retatrutide. Early trial data has shown substantial weight loss, generating significant anticipation.
- CagriSema (Novo Nordisk) — a combination of semaglutide with cagrilintide, an amylin analog, aiming to combine two distinct appetite-regulating hormone pathways.
- Survodutide (Boehringer Ingelheim / Zealand Pharma) — a dual GLP-1/glucagon receptor agonist in late-stage trials.
- Amycretin (Novo Nordisk) — a combined GLP-1/amylin receptor agonist, available in both injectable and oral formulations in trials.
Ongoing trials are also expanding what's known about existing approved drugs — for example, a 2026 trial (SURMOUNT-MAINTAIN) examined how well weight loss is maintained on tirzepatide at full versus reduced dose compared to stopping treatment entirely, finding that continuing treatment (even at a lower dose) maintained significantly more weight loss than switching to placebo (Horn et al., The Lancet, 2026, DOI (external link)) — relevant to ongoing questions about long-term treatment and weight regain after dose reduction. See our related guide on tapering vs. staying on a maintenance dose for more on this trial's implications.
The bottom line
GLP-1 medications represent two decades of incremental drug development — longer dosing intervals, broader hormone targeting, and now oral delivery — rather than a single recent breakthrough. Understanding that trajectory helps make sense of why newer drugs tend to outperform older ones, and why the pipeline of investigational drugs suggests this progression isn't finished yet.